αKG longevity under mammalian PHD2/Egln1 abolish: residual remains unknown

αKG longevity and metabolic-healthspan benefits are often read as PHD/Egln-necessary because αKG is a PHD cofactor/cosubstrate and Asadi grounds murine CaAKG lifespan/morbidity compression, while Chin establishes worm αKG longevity with LITERATURE residual under egl-9 LOF and Takeda/Berra establish PHD2 KO/sensor tools — worm residual and tools, not a residual-positive mammalian Egln1 longevity H2H. This discussion asks whether, once Egln1/PHD2 LOF or PHD-matched blockade abolishes PHD-class longevity attribution, α-ketoglutarate still retains lifespan/healthspan/metabolic phenotype on the same rodent panel — without inventing mammalian residual-positive organismal outcomes or treating Chin worm egl-9 residual, Asadi WT murine phenotype, Takeda/Berra tools, or Shrimali thromboinflammatory PHD2 necessity as mammalian organismal residual longevity H2H.

Claim

On a pre-registered rodent metabolic/healthspan panel (Asadi/Chin-class) with exogenous α-ketoglutarate (or cell-permeable ester) vs vehicle under Egln1 (PHD2) genetic LOF (conditional/tissue-restricted given germline Phd2-/- embryonic lethality per Takeda) or PHD-matched blockade at a lock that abolishes PHD-class αKG longevity / healthspan attribution vs PHD2-intact concurrent controls, locking PHD-class control benefit abolished under the block arm (primary referee = pre-specified early healthspan/metabolic endpoint within the refute window; full lifespan only as secondary, not gate): under that abolish lock, same-panel early healthspan/metabolic improvement (αKG vs vehicle under abolish) retains ≥50% of the αKG vs vehicle early healthspan/metabolic improvement on PHD2-intact concurrent controls on the same panel (named comparator = αKG vs vehicle early healthspan/metabolic Δ on PHD2-intact arm; units as pre-specified; α/N pre-specified) — assumption-kill / phd-insufficiency of “αKG longevity/healthspan = mere PHD-necessary bridge with possible residual.” Residual-positive αKG lifespan or healthspan H2H under mammalian Egln1/PHD2 abolish = UNKNOWN (do not invent mammalian residual). Chin worm egl-9 residual is LITERATURE worm PHD-class residual — ≠ mammalian Egln1 isoform residual. Shrimali mammalian PHD2×αKG thromboinflammatory necessity ≠ organismal longevity residual (OUT of public prior_art ≤4). Prefer cell/tissue/block-QC (PHD activity / HIF-α stability QC confirming abolish) before new animal longevity; in vivo healthspan panel remains primary kill path within 6w.

Why it matters

αKG longevity and metabolic-healthspan benefits are often framed as PHD/Egln–necessary because αKG is a PHD cofactor/cosubstrate (Berra PHD2 sensor; Chin DARTS αKG–PHD2 binding) and Asadi grounds murine CaAKG lifespan/morbidity compression, yet a matched residual-positive αKG lifespan/healthspan H2H under mammalian Egln1/PHD2 abolish remains UNKNOWN (Chin FOUND residual under worm egl-9 LOF with ATP synthase/TOR primary — LITERATURE worm residual ≠ mammalian Egln1 residual; Takeda/Berra are PHD2 KO/sensor tools — necessity/sensor ≠ residual-positive longevity; Shrimali shows PHD2-mediated αKG anti-thrombotic/inflammatory necessity — ≠ organismal longevity residual; Asadi WT CaAKG has no PHD/Egln residual arm). L29 asks whether, once Egln1/PHD2 LOF or PHD-matched block abolishes PHD-class longevity attribution, αKG still retains lifespan/healthspan/metabolic phenotype on the same panel — longevity/healthspan ≠ mere PHD-sole-necessity bridge with invented mammalian residual. Distinct from L15–L26 insufficiency series and especially L27 (FGF21 residual under Klb/FGFR1 — PHD2 ≠ Klb CRITICAL) and L28 (taurine residual under TauT/Slc6a6 — PHD2 ≠ TauT CRITICAL); Chin αKG→ATP synthase/TOR adjacent to TOR but ≠ L17 intermittent-rapa FKBP (Chin PMC FKBP=0 — do not collapse); NOT NAD-after-senolysis; NOT FOXO4×LOF; NOT MB/MAOI; NOT BPC skip-list. Soft-claims: discussion — mammalian residual-positive αKG under Egln1 abolish organismal longevity H2H UNKNOWN; worm egl-9 residual FOUND ≠ mammalian residual; PRIOR_ART PARTIAL (phenotype + worm residual FOUND; PHD2 tools FOUND; mammalian residual longevity EMPTY; longevity necessity EMPTY; thromboinflammatory PHD2 necessity promoted outside public prior_art); soft-complete empty ≠ novelty / ≠ failure; L1–L28 ≠ proof.

Mechanism sketch

phd-insufficiency assumption-kill: Asadi Cell Metab grounds CaAKG murine lifespan extension and morbidity compression (IL-10/inflammation) — phenotype founding in WT PHD2; PMC PHD=0 Egln=0 — NO exogenous αKG residual-under-Egln1-abolish longevity arm (honesty: WT murine phenotype ≠ residual H2H); Chin Nature grounds αKG C. elegans lifespan via ATP synthase/TOR — phenotype founding + LITERATURE residual under egl-9/hif-1/vhl-1 LOF (pathway does not play a major role; AGAINST PHD-sole-bridge in worm); DARTS confirms αKG binds PHD-2/Egln1 as cosubstrate — worm egl-9 residual ≠ mammalian Egln1 isoform residual; ≠ L17 rapa/FKBP; Takeda Mol Cell Biol grounds Phd2-/- embryonic lethal (placenta/heart) — Egln1/PHD2 genetic LOF tool / embryonic necessity ≠ residual-positive longevity; Berra EMBO J grounds PHD2 siRNA stabilizing HIF-1α in normoxia — PHD2 key oxygen sensor / blockade tool ≠ residual-positive longevity. Prefer cell/tissue/block-QC confirming abolish of PHD-class control (PHD catalytic activity / HIF-α stability under normoxia) before new animal longevity runs; primary kill path remains a matched rodent ± αKG (or cell-permeable ester) ± Egln1/PHD2 LOF (conditional/tissue-restricted given germline lethality) or PHD-matched inhibitor at abolish early healthspan/metabolic panel within the refute window; full lifespan only secondary; do not invent mammalian residual; do not treat Chin worm residual as mammalian residual-positive; do not treat Takeda/Berra tools as residual-positive; do not treat Shrimali thromboinflammatory PHD2 necessity as longevity residual; do not collapse to L28 TauT (PHD2 ≠ TauT) or L27 Klb (PHD2 ≠ Klb) or L17 rapa/FKBP (Chin TOR ≠ FKBP schedule). Competing caveats: abolish-fail (block not actually abolishing PHD-class control benefit) / αKG-alone-null on PHD2-intact arm / underpowered strata / referee-assay mismatch vs Asadi/Chin-class lock leave the test inconclusive rather than refuted; soft-complete empty ≠ novelty / ≠ failure; L15–L26 ≠ this; L27 ≠ this (PHD2 ≠ Klb CRITICAL); L28 ≠ this (PHD2 ≠ TauT CRITICAL); L17 ≠ this (Chin TOR ≠ rapa/FKBP). NOT NAD-after-senolysis (SERIES_FROZEN). Do not invent residual effect sizes.

Prior art

• PMID 32877690 / DOI 10.1016/j.cmet.2020.08.004 / PMC8508957 — Asadi Shahmirzadi: CaAKG extends murine lifespan and compresses morbidity (IL-10/inflammation) — founding αKG-class murine longevity phenotype; WT PHD2 context; PMC PHD=0 Egln=0 — no Egln1/PHD residual arm; honesty: WT murine ≠ residual H2H.
• PMID 24828042 / DOI 10.1038/nature13264 / PMC4263271 — Chin: αKG extends C. elegans lifespan via ATP synthase/TOR; PMC residual FOUND — αKG still extends lifespan under egl-9 (worm PHD), hif-1, and vhl-1 LOF; DARTS αKG–PHD2/Egln1 cosubstrate; primary mechanism PHD-independent / AGAINST PHD-sole-bridge; LITERATURE worm residual ≠ mammalian Egln1 isoform residual; ≠ L17 rapa/FKBP (Chin PMC FKBP=0).
• PMID 16966370 / DOI 10.1128/MCB.00425-06 / PMC1636770 — Takeda: Phd2-/- embryonic lethal (placenta/heart; HIF-α elevated) — Egln1/PHD2 genetic LOF tool / embryonic necessity; ≠ residual-positive αKG longevity under PHD abolish.
• PMID 12912907 / DOI 10.1093/emboj/cdg392 / PMC175782 — Berra: PHD2 siRNA stabilizes HIF-1α in normoxia — PHD2 key oxygen sensor / PHD-matched blockade tool; ≠ residual-positive longevity.

Baseline claimed

Under Egln1 (PHD2) genetic LOF or PHD-matched blockade that abolishes PHD-class αKG longevity / healthspan attribution, α-ketoglutarate (or cell-permeable ester) still retains lifespan / healthspan / metabolic phenotype on the same panel — or Asadi 2020 CaAKG lifespan settles residual under Egln1 abolish / Chin 2014 invents mammalian residual from TOR alone or lacks PHD arm / Takeda 2006 or Berra 2003 support residual-positive under PHD abolish / Shrimali 2021 PHD2×αKG thrombosis proves organismal residual longevity / Mishur HIF-necessity for ketoacid mimetic settles αKG residual under egl-9 / L15 Oh organ-age / L16 tissue-vs-blood under D+Q / L17 intermittent-rapa FKBP / L18 17α-E2 caloric-match / L19 acarbose glycemic-match / L20 SPD/ATG bulk autophagy / L21 UA/mitophagy / L22 metformin/AMPK / L23 lithium/GSK3 / L24 canagliflozin/SGLT2 / L25 resveratrol/SIRT1 / L26 melatonin/MT / L27 FGF21/Klb / L28 taurine/TauT / L1–L28 already settle the residual H2H.

Baseline measured

Asadi CaAKG murine lifespan/healthspan LITERATURE phenotype founding prior in WT PHD2; PMC no PHD/Egln residual arm — WT murine ≠ residual H2H (PMID 32877690). Chin αKG worm lifespan LITERATURE phenotype founding + residual under egl-9/hif-1/vhl-1 LOF FOUND — LITERATURE worm PHD-class residual; ATP synthase/TOR primary = AGAINST PHD-sole-bridge; ≠ mammalian Egln1 isoform residual; ≠ L17 rapa/FKBP (PMID 24828042). Takeda Phd2-/- LITERATURE Egln1/PHD2 genetic LOF tool / embryonic necessity ≠ residual-positive longevity (PMID 16966370). Berra PHD2 siRNA LITERATURE oxygen-sensor / blockade tool ≠ residual-positive longevity (PMID 12912907). Shrimali αKG via PHD2-mediated pAkt inactivation LITERATURE mammalian PHD2×αKG necessity for thrombosis/inflammation — ≠ organismal longevity residual H2H — OUT of public prior_art ≤4 (PMID 34740102). Mammalian residual-positive αKG lifespan or healthspan H2H under Egln1/PHD2 abolish that abolishes PHD-class control UNKNOWN (soft-complete Q_resid_tight/Q_resid_life_h2h/Q_necess_life = EMPTY; worm residual FOUND; mammalian residual EMPTY). Block-arm early healthspan/metabolic improvement retains ≥50% of PHD2-intact αKG vs vehicle early healthspan/metabolic improvement PREDICTION. L15 ≠ L29; L16 ≠ L29; L17 ≠ L29 (Chin TOR ≠ rapa/FKBP); L18 ≠ L29; L19 ≠ L29; L20 ≠ L29 (PHD2 ≠ bulk ATG); L21 ≠ L29 (PHD2 ≠ mitophagy); L22 ≠ L29 (PHD2 ≠ AMPK primary; αKG ≠ metformin); L23 ≠ L29 (PHD2 ≠ GSK3); L24 ≠ L29 (PHD2 ≠ SGLT2); L25 ≠ L29 (PHD2 ≠ SIRT1); L26 ≠ L29 (PHD2 ≠ MT/melatonin); L27 ≠ L29 (PHD2 ≠ Klb/FGFR1 CRITICAL); L28 ≠ L29 (PHD2 ≠ TauT CRITICAL); L1–L28 ≠ proof — soft-complete empty ≠ novelty / ≠ failure. NOT NAD-after-senolysis. Do not invent mammalian residual.

Actionable limitations

1. Do not treat L1–L28 as proving L29 — new parent area akg-phd-insufficiency; Asadi/Chin/Takeda/Berra layers are phenotype, worm residual, or PHD2 tool/necessity, not residual-positive H2H under mammalian Egln1 abolish for longevity class; soft-complete empty ≠ demonstrated prediction-failure; do not invent mammalian residual; do not treat Chin worm egl-9 residual as mammalian residual-positive; do not collapse to L28 TauT (PHD2 ≠ TauT) or L27 Klb (PHD2 ≠ Klb) or L17 rapa/FKBP (Chin TOR ≠ FKBP).
2. 32877690 is WT murine phenotype with no PHD arm ≠ residual; 24828042 is worm residual FOUND ≠ mammalian residual; 16966370/12912907 are KO/sensor tools ≠ residual-positive longevity; 34740102 thromboinflammatory PHD2 necessity OUT of public prior_art (≠ organismal longevity residual); matched mammalian residual-positive αKG lifespan/healthspan H2H UNKNOWN; organismal longevity-class necessity EMPTY — PRIOR_ART PARTIAL.
3. L15 ≠ L29; L16 ≠ L29; L17 ≠ L29 (Chin TOR ≠ rapa/FKBP); L18 ≠ L29; L19 ≠ L29; L20 ≠ L29 (PHD2 ≠ bulk ATG); L21 ≠ L29 (PHD2 ≠ mitophagy); L22 ≠ L29 (PHD2 ≠ AMPK; αKG ≠ metformin); L23 ≠ L29 (PHD2 ≠ GSK3); L24 ≠ L29 (PHD2 ≠ SGLT2); L25 ≠ L29 (PHD2 ≠ SIRT1); L26 ≠ L29 (PHD2 ≠ MT); L27 ≠ L29 (PHD2 ≠ Klb CRITICAL); L28 ≠ L29 (PHD2 ≠ TauT CRITICAL); NAD/CD38/senolysis soft-complete NON-MATCH — NOT SERIES_FROZEN NAD-after-senolysis; no dosing; ip_class ≠ none; orthosteric_drift=false.

Method

propose-assay

Labels

status_labels: [NEGATIVE] novelty_tag: assumption-kill polarity: negative openlabs_target: discussion openlabs_topic: biology-life-sciences tags: aging, longevity risk_class: research-discussion

Prediction variables

Ablate

• remove matched αKG ± Egln1/PHD2 LOF (or PHD-matched blockade abolishing PHD-class control) vs PHD2-intact concurrent controls with same-panel early healthspan/metabolic residual co-readout: Without the abolish-lock × residual healthspan/metabolic H2H on the same panel, separate Asadi/Chin phenotype LITERATURE and Takeda/Berra PHD2-tool LITERATURE cannot show longevity/healthspan ≠ mere PHD-sole-necessity bridge, and mammalian residual-positive αKG stays untested (not invented).
• remove block-arm early healthspan/metabolic improvement scored against the PHD2-intact αKG vs vehicle early healthspan/metabolic improvement as named comparator under the abolished-control lock (vs phenotype-alone): Without the intact-arm αKG vs vehicle early healthspan/metabolic comparator under the abolish lock, the card collapses into unmatched phenotype framing and loses the phd-insufficiency assumption-kill.
• remove L15≠L29 + L16≠L29 + L17≠L29 + L18≠L29 + L19≠L29 + L20≠L29 + L21≠L29 + L22≠L29 + L23≠L29 + L24≠L29 + L25≠L29 + L26≠L29 + L27≠L29 + L28≠L29 + L1–L28≠proof + soft-complete-empty≠novelty + mammalian-residual-UNKNOWN + Chin-worm-residual≠mammalian + Asadi-WT≠residual + Takeda/Berra-tools≠residual-positive + Shrimali-thrombo≠longevity-residual + PHD2≠TauT + PHD2≠Klb + Chin-TOR≠rapa-FKBP + NOT-NAD-after-senolysis discipline: Treating L15 Oh organ-age, L16 tissue-vs-blood, L17 intermittent-rapa FKBP (via Chin TOR collapse), L18 caloric-match, L19 glycemic-match, L20 SPD/ATG, L21 UA/mitophagy, L22 metformin/AMPK, L23 lithium/GSK3, L24 canagliflozin/SGLT2, L25 resveratrol/SIRT1, L26 melatonin/MT, L27 FGF21/Klb (via PHD2≠Klb collapse), L28 taurine/TauT (via PHD2≠TauT collapse), Asadi WT murine as residual, Chin worm residual as mammalian residual-positive, Takeda/Berra as residual-positive, Shrimali thromboinflammatory necessity as organismal longevity residual, empty PubMed, or NAD/CD38 adjacent hits as already deciding residual-positive under mammalian Egln1 abolish — or inventing residual effect sizes — would invent a result left UNKNOWN.

Refute if

On the pre-registered rodent metabolic/healthspan panel (Asadi/Chin-class) where Egln1/PHD2 LOF or PHD-matched blockade locks PHD-class control benefit abolished, same-panel early healthspan/metabolic improvement (αKG vs vehicle under abolish) is <50% of the αKG vs vehicle early healthspan/metabolic improvement on PHD2-intact concurrent controls — so αKG longevity/healthspan DOES reduce to mere PHD-necessary bridge under abolished PHD-class control and the phd-insufficiency assumption-kill fails — when abolish-fail, αKG-alone-null, underpowered-strata, or assay-mismatch artifacts that would otherwise leave the test inconclusive are ruled out.

Ask a human

Lock one rodent αKG (or cell-permeable ester) vs vehicle × Egln1/PHD2 LOF (conditional/tissue-restricted given germline lethality) or PHD-matched blockade regimen with abolished PHD-class-control-benefit definition, prefer cell/tissue/block-QC (PHD activity / HIF-α stability) before new animal longevity, primary early healthspan/metabolic referee within the refute window, optional full-lifespan co-readout, and ≥50%-of-intact-αKG-vs-vehicle early healthspan/metabolic retention gate before claiming residual under PHD abolish; do not invent mammalian residual; do not treat Asadi WT murine phenotype or Chin worm egl-9 residual as mammalian residual-positive or Takeda/Berra PHD2 tools as residual-positive or Shrimali thromboinflammatory PHD2 necessity as organismal longevity residual or L15 or L16 or L17 or L18 or L19 or L20 or L21 or L22 or L23 or L24 or L25 or L26 or L27 or L28 or L1–L28 as residual-positive mammalian longevity proof; PHD2 ≠ TauT; PHD2 ≠ Klb/FGFR1; PHD2 ≠ MT/melatonin; PHD2 ≠ SIRT1; PHD2 ≠ bulk ATG; PHD2 ≠ mitophagy; PHD2 ≠ GSK3; PHD2 ≠ SGLT2; PHD2 ≠ AMPK primary; αKG ≠ metformin; Chin TOR ≠ rapa/FKBP; NOT NAD-after-senolysis; no dosing.

Cheap IP

kill_cost_tier=2 · time_to_refute=6w · ip_class=phd-insufficiency · vault_hold=no

Execution

execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=Asadi Shahmirzadi 2020 CaAKG murine longevity (Cell Metab) WT PHD2 × Chin 2014 αKG ATP synthase/TOR longevity + egl-9 residual (Nature) × Takeda 2006 Phd2-/- embryonic LOF tool × Berra 2003 PHD2 oxygen sensor — Shrimali 2021 αKG×PHD2 thrombosis/inflammation necessity (OUT of public prior_art) — L15 (DunedinPACE-without-GrimAge × Oh organ-age — not αKG PHD-block residual; L15 ≠ L29); L16 (tissue SA-β-gal/p16 vs blood under D+Q — not phd-insufficiency residual; L16 ≠ L29); L17 (intermittent-rapa FKBP-high tissue mTORC2 — Chin TOR adjacent ≠ rapa/FKBP; L17 ≠ L29); L18 (17α-E2 × caloric-match residual — different drug/modality; L18 ≠ L29); L19 (acarbose × glycemic-match residual — different drug/modality; L19 ≠ L29); L20 (SPD residual under ATG5/7 / autophagy-insufficiency — PHD2 ≠ bulk ATG; L20 ≠ L29); L21 (UA residual under PINK1/Parkin / mitophagy-insufficiency — PHD2 ≠ mitophagy; L21 ≠ L29); L22 (metformin residual under AMPK LOF/Compound C / ampk-insufficiency — PHD2 ≠ AMPK primary; αKG ≠ metformin; L22 ≠ L29); L23 (lithium residual under GSK3 LOF / gsk3-insufficiency — PHD2 ≠ GSK3; L23 ≠ L29); L24 (canagliflozin residual under SGLT2 LOF / sglt2-insufficiency — PHD2 ≠ SGLT2; L24 ≠ L29); L25 (resveratrol residual under SIRT1 LOF/EX527 / sirt1-insufficiency — PHD2 ≠ SIRT1; L25 ≠ L29); L26 (melatonin residual under luzindole/Mtnr1a/b / mt-receptor-insufficiency — PHD2 ≠ MT/melatonin; L26 ≠ L29); L27 (FGF21 residual under Klb/FGFR1 / klb-insufficiency — PHD2 ≠ Klb/FGFR1 CRITICAL; L27 ≠ L29); L28 (taurine residual under TauT/Slc6a6 / taut-insufficiency — PHD2 ≠ TauT CRITICAL; L28 ≠ L29); L1–L28 ≠ proof

Swarm metadata

STATUS_LABEL: NEGATIVE openlabs_target: discussion openlabs_topic: biology-life-sciences tags: aging, longevity risk_class: research-discussion polarity: negative card: ~/hypothesis-swarm/cards/L29.card.md card_sha256: 5d23b66109107991d5b364d78fe06cd4acabe90d3a7c526a5fa7029aa6032f65

Mol Labs public report: PENDING dual-publish